Presarcopenia in Patients with Vitiligo: A Case Control Study
Faiq I. Gorial¹, Sarah Khalaf Jehad², Salwa Faris Taha³, Aseen Adil Tawfeeq⁴
¹Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, ²Rheumatology Unit, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq, ³Department of Dermatology, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq, ⁴Kirkuk Hospital, Kirkuk, Iraq

ABSTRACT

Background: Sarcopenia is a muscle disease with significant morbidity and mortality. Vitiligo is a common autoimmune inflammatory disease which results from absence, deficiency, or dysfunction of melanocytes. Links between sarcopenia and autoimmune inflammatory processes were reported. However, no previous reports on association between sarcopenia and vitiligo were identified. Objective: To assess presarcopenia in patients with vitiligo and to evaluate the effect of sociodemographic and clinical characteristics of vitiligo patients of sarcopenia if present. Subject and methods: This case control study included 63 patients with Vitiligo and 63 apparently healthy control group matched in age and gender. Sarcopenia was diagnosed by measuring the Appendicular Lean Mass Index. Cut off point required for sarcopenia is <6 for women and <7 for men. Sociodemographic and clinical characteristics were recorded. Sarcopenia was diagnosed according to the 2018 revised European consensus on definition and diagnosis of sarcopenia. Results: Mean age of vitiligo patients was 38.7 ± 14.0 years (range: 20-69 years) and for controls 39.9 ± 11.6 years (range: 20-70 years) (p=0.604). Female were 34 (54.0%) and 29 (46.0%) males, while in the controls 30 (47.6%) were females and 33 (52.4%) males (p=0.604). Presarcopenia was significantly higher in Vitiligo compared to controls. Vitiligo increases the risk of having presarcopenia by about five-fold (OR [95%CI]=4.706[1.26-17.61], p=0.013).Only BMI was significantly negatively correlated with presarcopenia. BMI decreases the risk of having presarcopenia by odds ratio of 0.837 (0.032). other baseline characteristics had no significant impact of presarcopenia in vitiligo (P model<0.01, R² =0.46 Accuracy= 0.57 AUC=0.92). Conclusions: Vitiligo was significantly positively correlated with presarcopenia and increased the risk of presarcopenia by about five-fold.

Keywords: Sarcopenia, vitiligo, sarcopenia and vitiligo
INTRODUCTION
Sarcopenia is a progressive and generalised skeletal muscle disease associated with increased adverse outcomes including falls, fractures, physical disability, and mortality.1 Muscle mass and strength vary across lifetime, generally increasing with growth in youth and young adulthood, being maintained in midlife and then decreasing with ageing.1 Sarcopenia has long been associated with ageing, but the development of sarcopenia is now recognized to begin earlier in life. Presarcopenia corresponds to the preliminary stage of sarcopenia.1,2 Many factors can lead to sarcopenia3-7: 1) increased IL6 as proinflammatory cytokine; 2) low testosterone level and increased cortisol level, in addition to 3) low vitamin D3 level. On the other hand, vitiligo is an autoimmune destruction of melanocytes affecting skin, hair, and mucosa.3,4 The main pathogenesis: 1) increased proinflammatory cytokine (IL6)5,6; 2) decreased testosterone level and increased serum level of cortisol10; 3) very low vitamin D3 levels have been noted in patients with a variety of vitiligo vulgaris.11,12
Because of the shared pathogenesis of sarcopenia and vitiligo in increased serum IL6, serum cortisol level, low testosterone level, and low vitamin D3 level, so a possible link between sarcopenia and osteoporosis may be present. Accordingly, this study was designed to assess the relationship between sarcopenia and vitiligo and to evaluate the effect of sociodemographic and clinical characteristics of vitiligo patients on sarcopenia if present.

SUBJECT AND METHODS
Study design and settings
This case-control study was conducted at Dermatology Centre and Rheumatology Unit of Baghdad Teaching Hospital/ Medical City complex from September 2018 to the end of May 2019. Out of a total of 126 Iraqi participants, 63 patients were diagnosed with vitiligo by the dermatologists and 63 apparently healthy controls matched in age and gender were enrolled in the study. Ethical approval was taken from the Department of Medicine, College of Medicine, University of Baghdad with number 30010 on 12th November, 2018. Informed written consent was taken from all the participants in the study.

Sample Selection
Patients and controls were recruited consecutively. Eligible patients for the study were vitiligo patients with age >18 years diagnosed by a dermatologist according to clinical features. Exclusion criteria included: Individuals who were unwilling to undergo a dual energy X-ray absorptiometry (DXA). Pregnant individuals, individuals with acute or chronic infection, diabetes mellitus, history of thyroid disease, hepatic/renal dysfunction, established malignancy, surgery,13 other systemic inflammatory arthritis and/or autoimmune connective tissue, and patients with history of surgery <6 months were excluded. Malnutrition was excluded by mini nutritional assessment.14 The controls were obtained from apparently healthy medical staff volunteers and visitors attending the outpatient clinics. These healthy controls did not have any history of autoimmune rheumatic disease.

Clinical and Laboratory Assessment
Data were collected using a data collection sheet containing questionnaires for the patients and controls. Sociodemographic and clinical data included: age, gender, educational level and marital status, height was measured in meters (m) without shoes using a stadiometer, and weight was measured in kilograms (Kg), body mass index (BMI) was calculated according to the World Health Organization.15 Vitiligo evaluation included disease duration, types of Vitiligo and body surface area,16 and medication used. The laboratory results for complete blood count, liver function test, renal function test, erythrocyte sedimentation rate, thyroid stimulating hormone, serum level of calcium, fasting/random blood sugar, antinuclear antibody, and rheumatoid factor (if needed) were recorded.

SARCOPENIA ASSESSMENT
Measurement of body composition
Body composition was obtained using DXA scan, (393 rue Charles Lindbergh, 34130 Mauguio, France) machine was used for quantifying muscle mass, fat mass, lean mass, and bone mineral density (BMD) measured. The total lean mass (LM) of the extremities (total summation of muscle mass of the four limbs) was calculated and the diagnosis of sarcopenia was made via measuring the appendicular lean Mass Index (ALMI) by calculating the LM/height2 (kg/m2). Cut off point required for sarcopenia is <6 for women and <7 for men.1

Assessment of muscle strength
Handgrip strength was measured using electronic hand dynamometer (CAMRY), tests were performed in an upright standing position, arms down by the side. Two to three test trials were performed, for both the dominant and non-dominant hand. The best trial was included in the analysis.17

Physical activity measurement
Physical activity is measured by 4-m usual walking speed test with a stopwatch to measure gait timing. The cut-off speed ≤0.8 m/s is as an indicator of severe sarcopenia.18

Statistical analysis
Statistical software SPSS v24 (IBM, New York, NY, USA)
was used for analysis. Kolmogorov Smirnoff test was used to assess normality of continuous variables. Data was expressed as mean± SD for normally distributed continuous variables and numbers (percentages) for categorical variables. Student’s t test was used to find the difference between normally distributed continuous variables and Chi square test for categorical variables. Binary logistic regression analysis was used to assess the effect of baseline characteristics on sarcopenia. Variables included in the binary logistic regression analysis were age, gender, BMI, smoking status, vitiligo duration and type, and steroids, phototherapy, immunotherapy, and depigmentation therapy users. Missing data were checked, and basic assumptions met for logistic regression. P value < 0.05 was considered statistically significant.

RESULTS
A total of 126 participants were included in the study, out of which 63 were vitiligo patients and 63 apparently healthy controls. The mean age of vitiligo patients was 38.7 ± 14.0 years (range: 20-69 years) which was comparable with that of the controls 39.9 ±11.6 years (range: 20-70 years) (p=0.604). Female were 34 (54.0%) and 29 (46.0%) male, while in the controls 30 (47.6%) were female and 33 (52.4%) male (p=0.476). Other baseline characteristics are shown in Table 1.

Presarcopenia was statistically significantly higher in vitiligo patients compared to controls. Vitiligo increases the risk of having presarcopenia by about five-fold (OR [95%CI]=4.706 [1.26-17.61], p=0.013) as shown in Figure 1.

On multiple regression analysis to assess the impact of baseline characteristics on presarcopenia in vitiligo patients, we found only BMI was significantly negatively correlated with presarcopenia. BMI decreases the risk of having presarcopenia by odds ratio of 0.837 (p=0.032) as in Table 2.

### Table 1. Baseline characteristics of vitiligo patients and controls.

| Variables                        | Vitiligo=63 | Controls=63 | p-value |
|----------------------------------|-------------|-------------|---------|
| Age (years), mean ± SD           | 38.7 ± 14.0 | 39.9 ± 11.6 | 0.604   |
| Gender, n (%)                    |             |             |         |
| Female                           | 34 (54.0%)  | 30 (47.6%)  | 0.476   |
| Male                             | 29 (46.0%)  | 33 (52.4%)  |         |
| BMI (kg/m²), mean ± SD           | 27.6 ± 7.4  | 30.6 ± 5.7  | 0.012 S |
| Smoking, n (%)                   |             |             |         |
| Active                           | 9 (14.3%)   | 6 (9.5%)    | 0.180   |
| Non-smoker                       | 20 (31.7%)  | 32 (50.8%)  |         |
| Ex-smoker                        | 8 (12.7%)   | 7 (11.1%)   |         |
| Passive                          | 26 (41.3%)  | 18 (28.6%)  |         |
| Vitiligo duration, mean ± SD, range | 13.3 ± 12.7, (0.5-64) |  |
| Vitiligo types, n (%)            |             |             |         |
| Vulgaris                         | 45 (71.4%)  |             |         |
| Universal                        | 9 (14.3%)   |             |         |
| Focal                            | 7 (11.1%)   |             |         |
| Acrofacial                       | 2 (3.2%)    |             |         |
| BSA (%), mean ± SD               | 31.4 ± 32.5 |             |         |
| Therapy, n (%)                   |             |             |         |
| Topical steroids                 | 52 (82.5%)  |             |         |
| Phototherapy                     | 22 (34.9%)  |             |         |
| Immune therapy (TCI)             | 39 (61.9%)  |             |         |
| Depigmentation                   | 5 (7.9%)    |             |         |

Values are means ± SD or numbers and percentages. BMI, Body mass index; kg, kilogram; m², meter square; S, significant; n, number; P value, probability value (<0.05). TCI, Topical calcineurin inhibitors.
DISCUSSION
The interest about sarcopenia is growing considerably. There has been a rapid growth in the scientific literature over the past years, investigating sarcopenia and related health outcomes. To the best of our knowledge, this is the first study that assessed the prevalence of sarcopenia in vitiligo patients. The current study showed that the risk of presarcopenia was increased about five-fold in vitiligo patients compared to controls. BMI was negatively correlated with presarcopenia and other baseline characteristics had no impact on presarcopenia in vitiligo patients.

Possible explanation of increased risk of presarcopenia in vitiligo may be related to several factors including autoimmunity and increased proinflammatory cytokines, psychological stress, dietary restrictions, low vitamin D level, and corticosteroids use. Many studies showed that patients with autoimmune disease have a slightly higher risk of sarcopenia when are compared to control group; this finding may affect the quality of life and promote the increasing of morbidity in such patients. A previous Iraqi study revealed that the risk of sarcopenia was higher in rheumatoid arthritis patients in compare to healthy subjects of the same age. Another Iraqi study assessed body composition in Iraqi women with systemic lupus erythematosus revealed that there was no significant difference between body composition of lupus patients and controls. Also, it has been reported that patients with spondyloarthritis and systemic sclerosis tend to have higher risk of sarcopenia than matched controls. In systemic sclerosis, sarcopenic patients were found to have longer disease duration, worse lungs, and skin involvement. Studies indicate the intrinsic relationship between sarcopenia and diabetes mellitus pathophysiological mechanisms. Haemoglobin levels were associated with the parameters of body composition, while the decreases in muscular strength measures occur in the presence of anaemia. Glucocorticoid (GC) used in treatment of autoimmune disease could also increase muscle atrophy: GC-induced muscle atrophy is characterised by fast-twitch, glycolytic muscles, while atrophy is illustrated by decreased fibre cross-sectional area, reduced myofibrillar protein content and increased protein breakdown, and decreased protein synthesis. Increased muscle proteolysis, in particular through the

Table 2. Logistic regression analysis to assess the impact of baseline characteristics of vitiligo patients on presarcopenia.

| Predictor         | p     | Odds ratio | 95% CI Lower | Upper  |
|------------------|-------|------------|--------------|--------|
| Age              | 0.857 | 0.993      | 0.9239 1.068 |        |
| Female gender    | 0.113 | 4.867      | 0.6868 34.483 |    |
| BMI              | 0.032 | 0.837      | 0.7112 0.985 |        |
| Smoking          | 0.138 | 1.938      | 0.8080 4.650 |        |
| Vitiligo duration| 0.153 | 1.068      | 0.9758 1.170 |        |
| Vitiligo Type    | 0.751 | 1.172      | 0.4401 3.121 |        |
| Steroids         | 0.993 | 6.76e+8    | 0.0000 Inf  |        |
| Phototherapy     | 0.298 | 0.283      | 0.0264 3.040 |        |
| Immune therapy   | 0.685 | 1.487      | 0.2183 10.124 |    |
| Depigmentation   | 0.997 | 4.22e-8    | 0.0000 Inf  |        |

P model<0.01 R²=0.46 Accuracy= 0.57 AUC=0.92 BMI, body mass index; inf, infinity.
activation of the ubiquitin proteasome and the lysosomal systems, is considered to play a major role in the catabolic action of GC.26

Limitations
This study has some limitations: small sample size, short duration, no follow up, and inability to exclude steroids. However, this can be solved by a larger, longer, prospective study to validate the results. Despite these limitations, this study was the first study that evaluated sarcopenia among vitiligo patients.

CONCLUSION
Presarcopenia was significantly higher in vitiligo patients compared to controls. Other sociodemographic and clinical characteristics of vitiligo patients had no significant effect on presarcopenia except for BMI, which was negatively correlated with it. These findings may suggest early screening for sarcopenia is important for diagnosis and treatment, and subsequently preventing sarcopenia complication and burden on patient quality of life.

ACKNOWLEDGEMENTS
We thank all the participants in the study.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

FUNDING
This research received no grant from any funding agency in the public, commercial or not-for-profit sectors.

AUTHOR CONTRIBUTIONS
The authors (Faig I. Gorial, Sarah Khalaf Jehovah, Salwa Faris Taha, and Aseen Adil Tawfeeq) participated in the study design, data collection, and literature search. Data was analysed by FIG, who also wrote the paper. All authors read and approved the final manuscript.

REFERENCES
1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis of sarcopenia. Age Ageing 2018;47:48(1):16-31.
2. Kobayashi K, Ando K, Tsushima M, Machino M, Cia K, Morozumi M, et al. Predictors of presarcopenia in community-dwelling older adults: A 5-year longitudinal study. Mod Rheumatol 2019 Nov:29(6):1053-8.
3. Ezedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi IH, et al. Vitiligo is not a cosmetic disease. J Am Acad Dermatol 2015;73:883-5.
4. Mason CP, Gawrakoder DJ. Vitiligo presentation in adults. Clin Exp Dermatol 2005;30:344-5.
5. Ryall JC, Schertzer JD, Lynch GS. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. BioGerontology 2008;1;59(3):M249-54.
6. Greenlund LJ, Nair KS. Sarcopenia—consequences mechanisms and potential therapies. Mech Ageing Dev 2003; 124:287-99.
7. Mijarerends DM, Koster A, Schols JM, Meijers JM, Halfens RJ, Gudnason V, et al. Physical activity and incidence of sarcopenia: the population-based AGES—Reykjavik Study. Age Ageing 2016;1;45(5):614-20.
8. Abdallah M, El-Mofy M, Anbar T, Rasheed H, Esmat S, Al-Tawdy A, et al. CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study. Pigment Cell Melanoma Res 2018;31(2):330-6.
9. Toosi S, Orlow SJ, Manga P. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol 2012;132(11):2601-9.
10. Kotb El-Sayed MI, Abd El-Ghary AA, Mohamed RR. Neural and endocortical Pathobiology of Vitiligo: comparative study for a hypothesized Mechanism. Front Endocrinol 2018 Apr 25;9:197.
11. Malhotra N, Dytoc M. The pathogenesis of vitiligo. J Cutan Med Surg 2013;17(3):153-72.
12. Pahwa P, Mehta M, Khaitan BK, Sharma VK, Ramam M. The psychosocial impact of vitiligo in Indian patients, Indian J Dermatol 2013;79(5):679.
13. Welch C, Hassan-Smith ZK, Greig CA, Lord JM, Jackson TA. Acute sarcopenia secondary to hospitalisation—an emerging condition affecting older adults. Aging Dis 2018;9(1):151.
14. Vellas B, Villars H, Abellan G, Soto ME, Rolland Y, Guigoz Y, et al. Overview of the MNA® - Its History and Challenges. J Nutr Health Aging 2008;10:456-66.
15. World Health Organization. Obesity: preventing and managing the global epidemic. World Health Organization 2000;894(i-xii):1-253.
16. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003;148(2):373-4.
17. Abe T, Lovenne JP. Handgrip strength dominance is associated with difference in forearm muscle size. J Phys Ther Sci 2015;27;7:2147-9.
18. Maggio M, Ceda GP, Ticinesi A, De Vita F, Gelmini G, Costantino C, et al. Instrumental and non-instrumental evaluation of 4-meter walking speed in older individuals. PLoS One 2016;11;4:e0153583.
19. Ureña MC, Cruz SC, Bonilla GM, Ureña SG, Medina AB, Orozco VR, et al. AB0718 Autoimmune sarcopenia in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2013;71(Suppl 3):679.
20. Riad A, Abdulatif N. The prevalence of sarcopenia in a sample of Iraqi patients with RA. Thesis submitted to IBFMS 2018;3:16:6-7.
21. Gorial FI, Mahmoud ZA, Al Obaidi S. Body Composition in Iraqi Women With Systemic Lupus Erythematosus. Glob J Health Sci 2019;11(1):3-4.
22. Aguilar R, Meirinhos T, Embrosio C, Barcelos A, Sequeira J. SARCOPSA-Sarcopenia in spondyloarthritics patients. Acta Reumatol Port 2014 Oct 1;39(4):322-6.
23. Cammi C, Caramaschi F, Venturini A, Bertoldo E, Vantaggiato E, Viapiana O, et al. Malnutrition and sarcopenia in a large cohort of patients with systemic sclerosis. Clin Rheumatol 2018;1;45(7):987-97.
24. Souza AB, Nascimento DA, Rodrigues U, Charone CC, Lopes GL, Lima S, et al. Association between sarcopenia and diabetes in community dwelling elderly in the Amazon region–Viver Mais Project. Arch Gerontol Geriatr 2019 Jul 1;83:121-5.
25. Cesari M, Penninx BW, Laurenzi F, Russo CR, Carter C, Bandinelli S, et al. Hemoglobin levels and skeletal muscle: results from the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2004;1;59(3):M249-54.
26. Schakman O, Kalista S, Barbé C, Loumaya A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013;1;45(10):2163-72.